Iron status in HIV-1 infection: implications in disease pathology by Banjoko, Olatunbosun S. et al.
RESEARCH ARTICLE Open Access
Iron status in HIV-1 infection: implications in
disease pathology
S Olatunbosun Banjoko1,5*, Falilat A Oseni1, Rachel A Togun2, Olaniyi Onayemi3, Beatrice O Emma-Okon4
and Julius B Fakunle4
Abstract
Background: There had been conflicting reports with levels of markers of iron metabolism in HIV infection. This
study was therefore aimed at investigating iron status and its possible mediation of severity of HIV- 1 infection
and pathogenesis.
Method: Eighty (80) anti-retroviral naive HIV-1 positive and 50 sero-negative controls were recruited for the study.
Concentrations of serum total iron, transferrin, total iron binding capacity (TIBC), CD4
+ T -lymphocytes, vitamin C,
zinc, selenium and transferrin saturation were estimated.
Results: The mean CD4
+ T-lymphocyte cell counts, serum iron, TIBC, transferrin saturation for the tests and controls
were 319 ± 22, 952 ± 57 cells/μl (P < 0.001), 35 ± 0.8, 11.8 ± 0.9 μmol/l (P < 0.001), 58.5 ± 2.2, 45.2 ± 2.4 μmol/l
(P < 0.005) and 68.8 ± 3.3, 27.7 ± 2.2%, (P <0.001), respectively, while mean concentrations of vitamin C, zinc
and selenium were 0.03 ± 0.01, 0.3 ± 0.04 (P < 0.001), 0.6 ± 0.05, 11.9 ± 0.26 μmol/l (P < 0.001) and 0.1 ± 0.01,
1.2 ± 0.12 μmol/l (P < 0.001) respectively. Furthermore, CD4+ T-lymphocyte cell count had a positive correlation with
levels of vitamin C (r = 0.497, P < 0.001), zinc (r = 0.737, P < 0.001), selenium (r = 0.639, P < 0.001) and a negative
correlation with serum iron levels (r = −0.572, P < 0.001).
Conclusion: It could be inferred that derangement in iron metabolism, in addition to oxidative stress, might have
contributed to the depletion of CD4
+ T cell population in our subjects and this may result in poor prognosis of t
he disease.
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Background
The human immunodeficiency virus 1 (HIV – 1) infec-
tion is known to affect virtually all the organs of
the body causing different metabolic derangements in
addition to the depression of the immune system [1].
These metabolic derangements include oxidative stress
due to persistent immune activation associated with un-
controlled HIV-1 replication leading to excessive reactive
oxygen species (ROS) generation and metabolic acidosis
[2-4]. Alterations in normal physiology as a result of im-
mune response in HIV infections may also involve mar-
kers of iron metabolism [5,6]. In a complex mechanism
yet to be unraveled, increased oxidative stress may result
in the release of bound iron from their apoproteins
therefore increasing the burden of plasma iron [7]. In
addition, excessive free radical production associated
with HIV – infection had been shown to participate in
T – lymphocyte depletion by triggering apoptosis and
cell death thereby weakening the immune system [8]
and causing the impairment of the antiviral defenses
mediated by T helper cells [9]. Furthermore, free radi-
cals generation had also been shown to be one of the
mediators of different metabolic alterations associated
with progression of HIV infection and positively correl-
ate with low concentrations of plasma zinc, selenium
and vitamin E, an indication of possible antioxidant
depletion [10-13].
Iron is an essential trace element present in biological
systems in either ferrous (Fe2+) or ferric (Fe3+) state.
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Transferrin, a β1 glycoprotein synthesized in the liver,
binds iron in the ferric form and transports it from the
storage site for utilization through a receptor mediated
pathway. The potential for the body iron concentration
to be raised in HIV infection due to their accumulation
in tissues such as liver, heart, pancreas and cells like
macrophages is enormous and may result in free radical
generation and accelerated catabolism of ascorbic acid
[14-16]. Experimental evidence had shown that serum
iron may be increased or decreased depending on the
stage of the disease. Although iron stores may decline in
early asymptomatic HIV infection probably because of
impaired absorption [17], they may however increase
with progression of the disease as iron accumulates in
the macrophages and other cells [18]. Hepcidin, a hor-
mone secreted by the hepatocytes is the key regulator of
iron metabolism and acts by binding to the trans-
membrane protein ferroportin responsible for the efflux
transport of iron from the cells. Sequel to hepcidin bind-
ing to ferroportin, it is internalized into the cytoplasmic
lysosomes and hydrolyzed thereby causing iron to
accumulate in the cells with resultant hypoferraemia.
Therefore, iron overload may occur when hepcidin is de-
ficient due to various reasons including defect in gene
expression of the protein or hepatic dysfunction [18,19].
Furthermore, potential availability of free iron due to ab-
normal physiology that may accompany iron overload
can cause DNA double strand breaks and oncogene acti-
vation [20]. Investigating the putative links between iron
status, disease progression and mortality is complicated
and some confounding factors which include modifica-
tion of iron status by the acute phase response (APR)
with resultant redistribution of iron and paradoxical iron
depletion in some body compartments and iron overload
in others had been identified. These inconsistencies in
impact of iron status on HIV infection, were therefore
the underpinnings of this study [14,15,21-23].
Methods
Ethical clearance
Ethical clearance was obtained from Obafemi Awolowo
University Teaching Hospital Complex Human Research
Ethics Committee and informed consent was obtained
from all the participants.
Tests and controls
Eighty (80) patients including 48 females (60%) and 32
males (40%) aged between 20 and42 years attending the
clinics of Obafemi Awowolo University Teaching Hos-
pital Complex, Ile-Ife, Nigeria who were newly diag-
nosed as HIV-1 positive, at different stages of the
infection and with no evidence of co-existing disease
were recruited for the study. Most were asymptomatic
and some were recruited from the routine screening at
the ante-natal clinic. The subjects were recruited sequel
to calculating the sample size, using the prevalence of
4.5% of the study area. Fifty (50) sero-negative indivi-
duals including 30 females (60%) and 20 males (40%)
aged between 22 and 45 years were also recruited as
controls. The exclusion criteria for all subjects included
ingestion of supplements like vitamin C and ferrous pre-
parations over a two-month period.
Screening tests for HIV-1 and HIV-2
Two different HIV screening kits were used for the de-
tection of sero-positivity using World Health Organiza-
tion (WHO) criteria. A rapid ELISA was done on whole
blood collected by finger prick using DetermineTM
HIV1/2 kit (Abbot Laboratories, Japan, and STAT-PAK
assay kit (Chembio Diagnostic Systems, USA). The
principle of the two test methods is based on antigen-
antibody reactions with colour indicators. Samples were
regarded as positive with a color change and negative
without it.
Collection of sample
Ten milliliters of venous blood was collected from each
participant into vacutainer tubes. Five milliliter of the
blood was placed in both EDTA and plain sample bot-
tles. Serum obtained from clotted blood was placed into
the plain bottle after clot retraction and centrifugation
at 25,000 rpm for five minutes using a bench centri-
fuge. The serum sample was thereafter stored frozen
at –70°C for later analysis for iron, transferrin, total
iron binding capacity (TIBC), zinc, selenium and vita-
min C. The blood sample in the EDTA bottle was
used immediately after collection for the determination
of CD+4 T-lymphocyte count.
Determination of CD+4 T-lymphocyte count
CD+4 T-lymphocyte count was done using Partec
Cyflow counter and Partec CD+4 T-lymphocyte easy
count kit. Twenty micro liters of whole blood was
placed in a test tube, thereafter, 20 μl of CD4- MAB/
PE (dye) was added and vortex -mixed gently. The
mixture was then incubated for 15 min at room
temperature. To this mixture, 80 μl of no-lyse buffer
was added and mixed. The pre-stained mixture was
aspirated into the Cyflow counter. The count result
was displayed electronically.
Determination of serum iron concentration
Serum iron was determined by the method of Garcic
(1979). The method is based on the formation of ternary
complex: chromazurol B (CAB) – cetyl-trimethyl ammo-
nium bromide (CTMA) - iron complex which was read
in a spectrophotometer at 623 nm. The concentration
of iron in samples and controls were determined from
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the interpolation of the absorbance on the known con-
centration of standard, as follows:
Absorbance of Test or Control
Absorbance of Standard
 17:9 μmol
l
Estimation of total iron binding capacity (TIBC)
Serum TIBC was determined using the spectrophoto-
metric method. Serum was treated with excess ferric
ions to ensure complete saturation of transferrin. Un-
bound excess iron was later adsorbed on aluminum
oxide and precipitated. The ferrous ions in the super-
natant were thereafter estimated by the previously
described method for serum iron estimation. The TIBC
was calculated as serum iron x 3 μmol/l. One milliliter
of ferric chloride was added to 0.5 ml of serum in a tube
and incubated at room temperature for 5 min, 1.0 ml of
aluminium oxide (Alox) was added, the mixture was
covered and placed in a vortex mixer for 10 min. The
tubes were removed and allowed to stand for 3 min. The
clear supernatant was used for iron estimation as
described earlier.
Transferrin saturation
Transferrin saturation was determined using the formula:
Serum Iron μmoll
 
TIBC
 100
1
%
Estimation of serum ascorbic acid concentration
Ascorbic acid was estimated according to the spectro-
photometric method of Henry et al. (1974). [24] Ascor-
bic acid in serum was oxidized to it’s de-hydro form by
cupric sulfate. The de-hydro- ascorbic acid was then
reacted with 2,4, di-nitro-phenylhydrazine in the pres-
ence of sulphuric acid to form a red colour whose inten-
sity is proportional to the concentration of ascorbic acid
and read at 520 nm. Ascorbic acid concentrations were
determined by interpolation of the absorbance of the
standard and its concentration.
Absorbance of Test or Control
Absorbance of Standard
 2:0mg
dl
Determination of serum zinc and selenium levels
Serum zinc and selenium levels were determined using
alpha - 4 flame atomic absorption spectrophotometer
(AAS) according to standard methods. De-proteinisation
was done by placing 1.0 ml of serum in the test tube
and adding 3 ml of 2 M HCl. The clear supernatant
was aspirated into the flame atomic absorption spec-
trophotometer (AAS) after adjusting the wavelength at
213.9 nm and 196.1 nm for zinc and selenium
estimation respectively. The concentrations were dis-
played electronically and the results were expressed
in μmol/l.
Statistical analysis
Data collected were analyzed using descriptive and infer-
ential statistics. Student’s T- test, Kruskaal Wallis and
Pearson’s correlation were the statistical methods
employed and Statistical Package for Social Sciences
(SPSS) software was utilized for these methods.
Study limitations
This was a retrospective rather than prospective study
making it difficult to obtain a sequential information on
iron status at different stages of the infection.
Results
Background characteristics
The test group had eighty (80) subjects including 48
females (60%) and 32 males (40%) aged between 20
and 42 years with mean ages and standard deviation
of 30.35 ± 5.47 years. The control group consisted of
fifty (50) sero-negative controls including 30 females
(60%) and 20 males (40%) aged between 22 and
45 years with mean age and standard deviation of
29.96 ± 6.31 years, t=0.373, (P=0.71). HIV-1 infection
cuts across the socio-economic strata in Nigeria, there-
fore socio-economic status was not considered a con-
founder in the study.
Markers of iron metabolism and immune status
The CD+4 T lymphocytes counts in our test subjects were
significantly lower than those of the controls [Table 1].
Serum iron, total iron binding capacity (TIBC) and
transferrin saturation were significantly different be-
tween the test and the control, P < 0.001 [Table 1].
Furthermore, in the test subjects, there were signifi-
cantly lower values in the three antioxidants estimated
viz vitamin C, P < 0.001, zinc, P < 0.001 and selenium
P < 0.0001 [Table 2]. In addition, there was a positive
Table 1 Mean concentrations, standard deviation and
P values of markers of iron metabolism and CD+4 T cell
count in tests and controls
Parameters Tests n=80 Controls n=50 P value
Mean ± SD Mean ± SD
CD+4 T cells/μl 319.6 ± 22 951.5 ± 57 <0.0001*
Serum Iron (μmol/l) 35.3 ± 0.8 11.8 ± 0.9 <0.001*
TIBC (μmol/l) 58.5 ± 2.2 45.2 ± 2.4 <0.001*
Transferrin Saturation (%) 68.0 ± 3.3 27.7 ± 2.2 <0.0001*
Values were expressed as mean ± standard deviation (SD).
P values <0.05 is significant.
*P denotes statistically significant value.
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correlation with CD4+ T cell count and negative cor-
relation with serum iron levels [Table 3].
Discussion
The significant variations in serum iron, transferrin sat-
uration and total iron binding capacity (TIBC) obtained
in HIV-1 infected subjects were indications of derange-
ment in iron metabolism. In addition, serum iron was
found to have negative correlation with CD4
+ T- lympho-
cytes [Table 3]. These findings corroborated the results
of some other workers who had previously observed that
iron impaired the CD4
+ T cell sub population in vitro
[15,25]. High plasma iron and body iron stores have the
potential of promoting free radical generation and oxida-
tive stress via the popular Fenton/Haber –Weiss reaction
[2,26-29]. The various metabolic derangements predispose
HIV patients to metabolic acidosis [30] which promotes
reduced binding of iron molecules to transferrin with re-
sultant increase in serum free iron [7]. It is of importance
to note that poorly liganded iron with resultant increased
body free iron which readily reacts with free radicals, par-
ticularly hydroxyl radicals had been observed in many
pathological processes and inflammatory diseases [41,42].
The possibility of occurrence of this scenario is therefore
high in an event of metabolic acidosis of HIV infection.
Furthermore, the fact that excessive free iron promotes
oncogene activation and tumour proliferation underscores
the possible involvement of derangement in iron metabol-
ism in incidence of HIV associated cancers like Kaposi’s
sarcoma and lymphomas [20].
Generation of free radicals has been implicated in the
depletion of the antioxidant stores and progressive loss
of CD4
+ T helper cells, which is indicated by the signifi-
cantly lower levels of vitamin C obtained in our test sub-
jects. In this study, the fact that CD4
+ T cell counts
correlated positively with the antioxidant levels [Table 3],
and supplementation with antioxidants such as zinc and
selenium have been shown to improve the immune sta-
tus in HIV-1 patients supports their usefulness as adju-
vants to antiretroviral therapy [31-34]. However, the low
antioxidant status observed in our study can also be
attributed to generalized cachexia, nutrient malabsorp-
tion and diarrhea commonly found in HIV-1 infections.
Another dimension of consequences of increased
plasma iron is the fact that iron- rich environment not
only renders the patients more susceptible to microbial
infections like Mycobacterium tuberculosis, Candida
albicans, Salmonella and hepatitis viruses B and C but
promotes their proliferation with a significant contribu-
tion to the morbidity and mortality that accompanies
HIV-1 infection.
The burden of elevated plasma iron can be further
compounded by alcohol ingestion, iron and multivita-
mins supplementation. Alcohol not only contains iron,
but aids the absorption of iron from the intestines [7].
The synergistic effect of iron supplementation and al-
cohol consumption in HIV infection can therefore be
better imagined. It is also pertinent to note that iron
supplements and iron containing multivitamins are
sold off the counters in pharmacies and their usage
without prescription are common practices particularly
in developing countries.
Other possible contributor to raised plasma iron is a
condition termed African iron overload, with distinct
features from the well characterized HLA linked haemo-
chromatosis observed in Caucasians and iron overload
unexplained by dietary, medicinal or excessive blood
transfusion with clinical significance which had been
observed in Africans and Americans of African descents
[35-39]. It is therefore plausible to suggest an interaction
between an unidentified gene and dietary iron content in
addition to derangement in intracellular iron metabolism
to be possible contributors to the elevated serum iron
observed in the patients studied. Our results however
confounded our expectation which the burden of hel-
minthiasis and malnutrition common in Africa could
have on serum iron levels. This underscores the clinical
significance of this study.
Although the retrospective nature of this study was a
limitation, there was no concurrence in the association of
iron status with severity of the disease in other prospective
and retrospective studies. For example, no correlation was
observed between plasma iron levels and markers of se-
verity of HIV disease in some Malawian sero-positive
Table 2 Mean concentrations, standard deviation and
P values of some serum antioxidants in tests and controls
Antioxidants Test n = 80 Control n = 50 P- value
Mean ± SD Mean ± SD
Vitamin C (μmol/l) 2.27 ± 0.57 17.03 ± 2.27 <0.001 *
Zinc (μmol/l) 0.6 ± 0.05 11.9 ± 0.26 <0.0001*
Selenium (μmol/l) 0.1 ± 0.02 1.2 ± 0.12 <0.0001*
Values were expressed as mean ± standard deviation (SD).
P values <0.05 is significant.
*P denotes statistically significant value.
Table 3 Correlation between CD4
+ T cells, serum iron and
antioxidants in test subjects
Parameters CD4
+ T cell count
Correlation P -value
Vitamin C (μmol/l) r = 0.497 P <0.001*
Zinc (μmol/l) r = 0.737 P <0.001*
Selenium (μmol/l) r = 0.639 P < 0.001*
Serum Iron (μmol/l) r = − 0.572 P < 0.001*
r values denotes degree of positive or negative correlation.
P value < 0.05 is statistically significant.
*P denotes significant positive or negative correlation.
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pregnant women [21]. Contrastly, in another cross sec-
tional study of some sero-positive pregnant Zimbabwean
women receiving iron supplementation, ferritin level was
found to be an independent predictor of viral load [40].
Although evidences of elevated iron status in HIV infec-
tion were observed in some similar retrospective studies
[5,6,40], this was however not the case in many others
[21,23]. Furthermore, associations between iron accumu-
lation and such adverse conditions like anaemia com-
monly unresponsive to iron supplementation, observed to
increase the incidence of opportunistic infection and
shorter survival periods led credence to the critical role of
iron metabolism in the pathogenesis of HIV disease [6,11].
From all indications, the virus-host iron status inter-
action is yet to be fully understood. While some viruses
selectively infect iron acquiring cells by binding to trans-
ferrin receptor-1 during cell entry, others alter the expres-
sion of proteins involved in iron homeostasis such as
human haemochromatosis protein; (HFE) and hepcidin.
Therefore iron overload associated with poor prognosis in
HIV-1 infection could be partly caused by the viruses
themselves [18]. Plausibly, understanding the regulation of
hepcidin production and how iron metabolism and viral
infection interact may in the near future stimulate the
development of new methods and strategies in the treat-
ment and management of the disease.
Conclusion
It could be inferred that derangement in iron metabol-
ism with resultant increase in plasma and total body
iron concentrations might have contributed to the de-
pletion of CD4
+ T cell population and the antioxidant
stores. It is therefore plausible to suggest that iron
supplementation and consumption of alcohol should
be discouraged in HIV infection, while antioxidant
supplementation could be recommended as adjuvant
to antiretroviral therapy. In addition, consideration
should be given to periodic evaluation of total antioxi-
dant status (TAS), acid–base balance and serum iron
in the treatment and management of HIV-1 infection.
This may likely improve the prognosis and immune re-
constitution post anti-retroviral therapy. It is equally
expedient to suggest the consumption of foods like
brightly coloured fruits, vegetables, green teas and blue
berries which are good sources of natural iron chela-
tors capable of mitigating excessive release of free iron
from their ligands by HIV infected individuals.
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